查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947955

地圖狀萎縮症治療市場：依藥物類別、給藥途徑、最終用戶、通路和疾病階段分類，全球預測，2026-2032年

Geographic Atrophy Drugs Market by Drug Class, Delivery Method, End User, Distribution Channel, Disease Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，地圖狀萎縮治療市場價值將達到 2.7924 億美元，到 2026 年將成長至 3.3727 億美元，到 2032 年將達到 11.8049 億美元，複合年成長率為 22.86%。

關鍵市場統計數據
基準年 2025 2.7924億美元
預計年份：2026年 3.3727億美元
預測年份 2032 11.8049億美元
複合年成長率 (%) 22.86%

策略性介紹概述了推動下一代地圖狀萎縮治療創新發展的科學、臨床和營運背景。

地圖狀萎縮症的治療需求已從數十年的未滿足狀態迅速發展成為一個快速演變的治療領域，這得益於新的生物學見解、先進的影像學終點指標以及不斷擴展的臨床試驗體系。本導言總結了干涉措施的臨床原理，概述了目前正在積極研究的關鍵治療方法，並提出了支付方、臨床領導者和行業戰略家在新的治療方法從臨床試驗過渡到常規臨床實踐過程中必須考慮的戰略問題。

生物學、監管先例和遞送技術的突破如何匯聚一堂，重新定義治療地圖狀萎縮的臨床路徑和商業策略

地圖狀萎縮的治療格局正在經歷一場變革性的轉變，這主要得益於科學技術的進步、監管先例的製定以及治療標準的改變。補體通路調節提供了首個臨床概念驗證，刺激了投資並擴大了研究方向，涵蓋了基因療法、緩釋平台和輔助神經保護策略。這些科學進展正在重塑臨床試驗終點，並鼓勵更廣泛地採用多模態影像生物標記和患者報告結局，以捕捉病灶指標之外的更有意義的療效。

評估2025年關稅變化對眼科藥物採購、本地化生產和分銷韌性的供應鏈壓力和戰略要務

2025年關稅的實施和貿易政策的調整，為包括地圖狀萎縮治療藥物在內的全球眼科治療供應鏈帶來了額外的營運複雜性。製造商和供應商在跨國採購時，某些活性藥物成分、特殊包裝和眼科給藥裝置的投入成本增加，迫使一些企業重新評估其製造地並調整供應商多元化策略。為此，一些研發企業開始從地理位置較近的供應商採購，並探索建立本地生產夥伴關係，以降低關稅波動帶來的風險。

基於詳細細分的洞察，整合治療方法、給藥途徑、臨床環境和患者群體，為地圖狀萎縮的臨床和商業策略提供資訊。

地圖狀萎縮症治療藥物的細分分析，揭示了不同產品類型、給藥途徑、臨床環境、商業管道、疾病階段和患者群體在臨床應用案例、研發路徑和相關人員優先事項方面的差異。依藥物類別分類，涵蓋生物製藥、基因療法和小分子藥物，其中生物製藥類別又細分為融合蛋白和單株抗體。每個類別都有其獨特的研發時間表、生產複雜性和監管考量，這些都會影響臨床開發和商業化策略。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和進入途徑將影響監管方法、臨床應用和供應策略。

區域趨勢正在影響地圖狀萎縮治療的監管預期、治療模式和患者就醫途徑。在美洲，監管機構對能夠延緩疾病進展和保留功能的證據持開放態度，醫療服務體係也在調整以適應重複玻璃體內注射和新興長效給藥平台的營運需求。此外，該地區多元化的支付方格局也要求制定個人化的醫療技術評估策略和真實世界證據，以支持醫保覆蓋決策。

策略性企業行動與夥伴關係模式，旨在加速地圖狀萎縮症治療領域的治療創新、最佳化給藥方式和產生實證醫學證據

眾多生物製藥公司、專業醫療設備開發商和學術聯盟正在為地圖狀萎縮症的治療創造一個既競爭又合作的環境。現有生物技術公司開發的補體通路抑制劑已獲得臨床概念驗證，推動了生物製藥和基因療法領域的創新浪潮。同時，大型製藥企業和專業醫療設備公司正在投資建立可擴展的生產能力和給藥平台，以支援更廣泛的臨床應用。

產業領導者提出的可操作優先事項整合了證據產生、交付創新、供應鏈韌性和支付方合作，以加速臨床應用。

產業領導者應優先考慮整合臨床證據產生、交付創新和供應鏈韌性的整合策略，以加速患者獲得治療，同時降低營運風險。首先，應將臨床開發項目與可操作的療效指標和真實世界數據收集相結合，確保療效訊號轉化為對支付方有價值的證據。對註冊登記和核准後監測的投入有助於進行長期價值對話，並將其納入臨床指南。同時，應優先考慮以患者為中心的交付解決方案，例如長效植入和微粒技術，以減輕治療負擔，並在不同的醫療環境中檢驗其安全性，從而促進其在門診中心、醫院和眼科診所的推廣應用。

採用透明的三角研究途徑，結合文獻綜述、監管審查、專家訪談和臨床路徑分析，以產生可操作的見解。

本研究綜合分析採用三角測量法，結合系統性文獻回顧、監管文件分析、專家訪談和臨床路徑圖譜，建構了地圖狀萎縮治療領域的整體情況。文獻回顧涵蓋了同行評審的臨床研究、視網膜生物學轉化研究以及關於視網膜成像和功能性結局指標的文章。監管材料和標籤指南的分析旨在確定核准視網膜疾病核准的證據要件和領先。

綜述強調，證據的一致性、治療方法的可行性和操作準備將決定地圖狀萎縮治療的長期臨床和醫學影響。

總之，地圖狀萎縮症的治療領域正處於一個轉折點，科學檢驗、監管先例和給藥創新相結合，為改變許多患者的疾病自然進程創造了切實的機會。補體標靶治療、新興的基因療法和緩釋給藥平台的整合，為延緩疾病進展和保護視力提供了多種途徑，但其在臨床實踐中的廣泛應用，取決於能否提供充分的證據證明其具有顯著的功能獲益、可控的安全性以及可行的給藥模式。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的地圖狀萎縮症治療市場

  • 生物製藥
    • 融合蛋白
    • 單株抗體
  • 基因治療
  • 低分子化合物

9. 依給藥途徑分類的地圖狀萎縮症治療市場

  • 玻璃體內注射
  • 緩釋系統
    • 植入
    • 細顆粒物
  • 外用製劑

第10章 以最終使用者分類的地圖狀萎縮症治療市場

  • 門診手術中心
  • 醫院
    • 二級護理
    • 三級醫療
  • 眼科診所

第11章 地圖狀萎縮症治療市場（依分銷管道分類）

  • 線上
  • 離線

第12章：依疾病階段分類的地圖狀萎縮症治療市場

  • 晚期
  • 最初的
  • 過渡時期

第13章 區域性地圖狀萎縮症治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 地圖狀萎縮症治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國地圖狀萎縮症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國地圖狀萎縮症治療市場

17. 中國：地圖狀萎縮症治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Graybug Vision, Inc.
  • Ionis Pharmaceuticals, Inc.
  • IVERIC bio, Inc.
  • Kodiak Sciences Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
Product Code: MRR-4F7A6D4FB6A5

The Geographic Atrophy Drugs Market was valued at USD 279.24 million in 2025 and is projected to grow to USD 337.27 million in 2026, with a CAGR of 22.86%, reaching USD 1,180.49 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 279.24 million
Estimated Year [2026] USD 337.27 million
Forecast Year [2032] USD 1,180.49 million
CAGR (%) 22.86%

A strategic introduction that frames the scientific, clinical, and operational context driving the next wave of Geographic Atrophy therapeutic innovation

Geographic atrophy is emerging from decades of unmet need into a rapidly evolving therapeutic domain shaped by novel biology, refined imaging endpoints, and an expanding clinical trial ecosystem. This introduction synthesizes the clinical rationale for intervention, summarizes the primary therapeutic modalities under active investigation, and frames the strategic considerations that payers, clinical leaders, and industry strategists must address as new interventions transition from trials into routine care.

Advances in understanding complement pathway dysregulation, neuroinflammation, and retinal cell survival mechanisms have converged with improved retinal imaging and functional outcome measures to create a viable pathway for therapeutic innovation. Translational work has accelerated candidate selection, while adaptive trial designs and real-world data collection are enabling earlier signals of durability and safety. At the same time, stakeholders face practical challenges around treatment delivery, patient selection, and long-term monitoring that will shape adoption and care pathways.

This section sets the foundation for deeper analysis by highlighting the interplay between scientific progress and operational considerations. It emphasizes how clinicians, health systems, and developers can align on evidence generation, post-approval surveillance, and care models that preserve sight while ensuring that new therapies integrate into existing ophthalmic practice efficiently and equitably.

How breakthroughs in biology, regulatory precedent, and delivery technologies are converging to redefine clinical pathways and commercial strategies for Geographic Atrophy therapies

The landscape for geographic atrophy therapeutics is undergoing transformative shifts driven by converging scientific advances, regulatory precedent, and changing standards of care. Complement pathway modulation has provided the first clinical proof of concept, catalyzing investment and a broadened research focus that now includes gene-based approaches, sustained-release platforms, and adjunct neuroprotective strategies. These scientific developments are reshaping clinical trial endpoints, prompting wider adoption of multi-modal imaging biomarkers and patient-reported outcomes to capture meaningful benefits beyond lesion metrics.

Concurrently, regulatory agencies have signaled pathways for expedited review when compelling evidence of slowed progression or preserved function emerges, which encourages companies to pursue robust safety monitoring and longer-term durability endpoints. Health systems and clinicians are adapting workflows to support recurring intravitreal administration and to integrate new sustained-delivery technologies that aim to reduce treatment burden. Payers are increasingly scrutinizing real-world effectiveness and value over time, prompting manufacturers to design outcomes-based agreements and to collect longitudinal evidence that aligns with payor priorities.

Taken together, these shifts create a dynamic environment in which scientific innovation, regulatory clarity, and care-delivery optimization interact. Stakeholders that anticipate changes in reimbursement, invest in patient-centric outcome measures, and develop delivery solutions that mitigate treatment burden will be better positioned to translate scientific promise into sustainable clinical impact.

Assessment of how 2025 tariff shifts created supply chain pressures and strategic imperatives for sourcing, manufacturing localization, and distribution resilience in ophthalmic therapeutics

The imposition of tariffs and trade policy adjustments in 2025 introduced additional operational complexities for global supply chains supporting ophthalmic therapeutics, including those for geographic atrophy. Manufacturers and suppliers experienced increased input costs for certain active pharmaceutical ingredients, specialty packaging, and ophthalmic delivery devices when components crossed tariffed borders, prompting some organizations to reassess manufacturing footprints and supplier diversification strategies. In response, several developers initiated sourcing shifts toward geographically proximate suppliers and examined localized manufacturing partnerships to reduce exposure to tariff volatility.

These developments also influenced logistics planning, with firms prioritizing inventory buffers for clinically critical components and accelerating qualification of secondary suppliers to maintain continuity of clinical trial supply and post-approval product availability. Health systems that rely on cross-border procurement for implants, microparticle carriers, and single-use procedural devices encountered variations in procurement timelines and unit costs, which required tighter coordination between supply chain, pharmacy, and clinical teams. Additionally, manufacturers working with global distribution networks adjusted contractual terms to allocate tariff-related risks and to ensure pricing transparency across regions.

Overall, the cumulative impact of tariff changes underscored the importance of resilient supply chain design and flexible commercial strategies. Organizations that proactively evaluated supplier risk, invested in regional manufacturing resilience, and built adaptable distribution agreements were better able to maintain clinical program continuity and respond to shifting procurement dynamics across regions.

Deep segmentation-driven insights that align therapeutic modality, delivery approach, care setting, and patient demographics to inform clinical and commercial strategy for Geographic Atrophy

A segmented view of geographic atrophy therapeutics clarifies clinical use cases, development pathways, and stakeholder priorities across product types, delivery approaches, care settings, commercial channels, disease stage, and patient demographics. Within drug class, the landscape encompasses Biologics, Gene Therapy, and Small Molecules, with the Biologics category further differentiated into Fusion Proteins and Monoclonal Antibodies; each class presents distinct R&D timelines, manufacturing complexities, and regulatory considerations that influence clinical development and commercialization strategies.

Delivery method plays a pivotal role in patient acceptance and clinical workflow, ranging from Intravitreal Injection to Sustained Release Systems and Topical Formulation, with Sustained Release Systems further divided into Implants and Microparticles; these options affect dosing frequency, procedural requirements, and long-term safety monitoring. End user segmentation highlights where interventions are delivered and managed, spanning Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics, while recognizing that Hospitals may operate at different levels of care such as Secondary Care and Tertiary Care, each with unique procedural capacities and referral patterns.

Distribution channel distinctions between Hospital Pharmacy, Retail Pharmacy, and Specialty Pharmacy shape reimbursement touchpoints and patient access pathways. Disease stage segmentation across Advanced Stage, Early Stage, and Intermediate Stage guides trial design and therapeutic intent, from slowing expansion of atrophy to preserving function earlier in the disease course. Patient age group stratification into 50 to 64, 65 to 74, 75 to 84, and 85 and above informs adherence dynamics, comorbidity management, and communication strategies for shared decision-making. By integrating these segment lenses, stakeholders can tailor clinical development, commercialization, and care delivery plans that align therapeutic attributes with the needs of patients and providers.

Regional dynamics and access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory approaches, clinical adoption, and supply strategies

Regional dynamics shape regulatory expectations, care delivery models, and patient access pathways for geographic atrophy interventions. In the Americas, regulatory authorities have been receptive to evidence demonstrating slowed disease progression and functional preservation, and health-care delivery systems are adapting to the operational demands of recurring intravitreal administration and newer sustained-delivery platforms. This region also presents diverse payer landscapes that require tailored health technology assessment strategies and real-world evidence to support coverage decisions.

Europe, Middle East & Africa present heterogeneous regulatory frameworks and reimbursement environments that demand localized evidence packages and engagement strategies with national health authorities and payer bodies. Clinicians in these regions increasingly rely on cross-border collaborative networks and registries to aggregate longitudinal outcomes, while differences in care infrastructure influence the adoption pace of advanced delivery systems and gene-based approaches. In several sub-regions, access constraints and procurement processes necessitate focused demonstrations of cost-effectiveness and implementation feasibility for widespread adoption.

Asia-Pacific encompasses a mix of established markets with advanced retinal care centers and emerging markets where diagnostic capacity and specialized ophthalmology services are expanding rapidly. Regulatory pathways in Asia-Pacific vary, with some agencies offering expedited review processes for therapies addressing significant unmet needs, while supply chain and localization considerations influence commercialization strategies. Across regions, aligning clinical development with local care models, reimbursement criteria, and manufacturing logistics remains essential to ensuring equitable access and sustained clinical impact.

Strategic company behaviors and partnership models that are accelerating therapeutic innovation, delivery optimization, and evidence generation for Geographic Atrophy interventions

A diverse set of biopharma companies, specialty device developers, and academic consortia are shaping the competitive and collaborative environment around geographic atrophy therapies. Established biotech firms that advanced complement pathway inhibitors have demonstrated clinical proof of concept and catalyzed a wave of innovation across both biologic and gene-based modalities. At the same time, larger pharmaceutical organizations and specialty device companies are investing in scalable manufacturing capabilities and delivery platforms to support broader clinical adoption.

Across the ecosystem, strategic partnerships between companies with complementary capabilities-such as those combining gene therapy know-how with ophthalmic delivery expertise-are accelerating development of next-generation interventions. Contract manufacturing organizations and specialty pharmacies have also become critical partners, providing the infrastructure for complex biologic production, cold-chain distribution, and patient support programs that are essential for outpatient administration and adherence. Furthermore, academic centers and cooperative research networks play a central role in validating novel endpoints and generating real-world evidence that informs regulatory and reimbursement discussions.

Companies that invest in differentiated delivery solutions, robust safety monitoring frameworks, and data generation plans that align with payer priorities will reinforce clinical credibility and commercial viability. Strategic licensing and co-development arrangements can bridge capability gaps and de-risk late-stage development while enabling broader geographic reach through localized manufacturing and distribution partnerships.

Actionable priorities for industry leaders to align evidence generation, delivery innovation, supply chain resilience, and payer engagement to accelerate clinical adoption

Industry leaders should prioritize an integrated strategy that balances clinical evidence generation, delivery innovation, and supply chain resilience to accelerate patient access while mitigating operational risks. Start by aligning clinical development programs with pragmatic outcome measures and real-world data collection so that efficacy signals translate into payer-relevant evidence; investing in registries and post-approval surveillance will support long-term value conversations and clinical guideline integration. Simultaneously, prioritize patient-centered delivery solutions that reduce treatment burden-such as sustained-release implants and microparticle technologies-while validating safety in diverse care settings to facilitate adoption across ambulatory centers, hospitals, and ophthalmology clinics.

Strengthening supply chain resilience is equally important. Evaluate supplier concentration risks, qualify secondary manufacturing partners, and consider regional manufacturing or packaging options to reduce exposure to policy-driven cost fluctuations and trade disruptions. From a commercial perspective, develop flexible contracting models that can accommodate value-based components and outcomes-linked agreements, and partner with specialty pharmacies and hospital pharmacy systems to streamline access pathways. Finally, cultivate multi-stakeholder engagement with clinicians, payers, and patient advocacy groups to co-create education, adherence programs, and care pathways that optimize treatment uptake and persistence.

By executing on these priorities, organizations can translate scientific advances into practical, equitable care solutions while safeguarding operational continuity and demonstrating sustainable value to health systems and patients.

A transparent, triangulated research approach combining literature synthesis, regulatory review, expert clinician interviews, and clinical pathway analysis to produce actionable insights

This research synthesis draws on a triangulated methodology combining systematic literature review, regulatory document analysis, expert interviews, and clinical pathway mapping to construct a comprehensive picture of the geographic atrophy therapeutic landscape. The literature review targeted peer-reviewed clinical studies, translational research on retinal biology, and publications describing retinal imaging and functional outcome measures. Regulatory materials and labeling guidance were analyzed to identify evidentiary expectations and precedent pathways for accelerated or conditional approval in degenerative retinal conditions.

To complement secondary sources, semi-structured interviews were conducted with retina specialists, clinical trial investigators, health-system pharmacy leaders, and supply chain executives to capture frontline operational realities and adoption barriers. These conversations informed the evaluation of delivery modalities, procedural workflows, and inpatient versus outpatient care models. Additionally, a review of clinical trial registries and company disclosures helped map therapeutic classes in active development, while public post-marketing safety communications and registry reports were used to assess real-world safety monitoring practices.

Findings were synthesized through iterative triangulation to reconcile clinical, regulatory, and operational perspectives. Throughout the process, emphasis was placed on transparency of evidence sources, validation against expert input, and the generation of actionable insights that are directly relevant to clinical decision-makers, commercial strategists, and policy professionals.

Concluding synthesis highlighting how evidence alignment, delivery feasibility, and operational readiness will determine the long-term clinical and care impact of Geographic Atrophy therapies

In conclusion, the field of geographic atrophy therapeutics is at an inflection point where scientific validation, regulatory precedent, and delivery innovation are creating tangible opportunities to alter the natural history of disease for many patients. The integration of complement-directed therapies, emerging gene-based approaches, and sustained-release delivery platforms offers multiple pathways to reduce progression and preserve vision, but real-world adoption will depend on evidence that demonstrates meaningful functional benefit, manageable safety profiles, and feasible care delivery models.

Operational readiness-spanning supply chain resilience, provider training, and coordinated reimbursement strategies-will determine how quickly new therapies become widely available. Stakeholders that align clinical development with payer-relevant outcomes, optimize delivery to minimize treatment burden, and invest in robust long-term monitoring will be positioned to deliver the greatest clinical and societal benefit. Ultimately, translating scientific promise into sustained improvements in patient outcomes requires collaboration across industry, clinicians, payers, and patient communities to ensure therapies are safe, effective, and accessible.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Geographic Atrophy Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Fusion Proteins
    • 8.1.2. Monoclonal Antibodies
  • 8.2. Gene Therapy
  • 8.3. Small Molecules

9. Geographic Atrophy Drugs Market, by Delivery Method

  • 9.1. Intravitreal Injection
  • 9.2. Sustained Release Systems
    • 9.2.1. Implants
    • 9.2.2. Microparticles
  • 9.3. Topical Formulation

10. Geographic Atrophy Drugs Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
    • 10.2.1. Secondary Care
    • 10.2.2. Tertiary Care
  • 10.3. Ophthalmology Clinics

11. Geographic Atrophy Drugs Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Geographic Atrophy Drugs Market, by Disease Stage

  • 12.1. Advanced Stage
  • 12.2. Early Stage
  • 12.3. Intermediate Stage

13. Geographic Atrophy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Geographic Atrophy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Geographic Atrophy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Geographic Atrophy Drugs Market

17. China Geographic Atrophy Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Apellis Pharmaceuticals, Inc.
  • 18.9. Astellas Pharma Inc.
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol Myers Squibb Company
  • 18.13. Catalyst Biosciences, Inc.
  • 18.14. EyePoint Pharmaceuticals, Inc.
  • 18.15. Graybug Vision, Inc.
  • 18.16. Ionis Pharmaceuticals, Inc.
  • 18.17. IVERIC bio, Inc.
  • 18.18. Kodiak Sciences Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Novartis AG
  • 18.21. Pfizer Inc.
  • 18.22. Regeneron Pharmaceuticals, Inc.
  • 18.23. Roche Holding AG
  • 18.24. Sanofi

LIST OF FIGURES

  • FIGURE 1. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MICROPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MICROPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MICROPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TOPICAL FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TOPICAL FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TOPICAL FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTERMEDIATE STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTERMEDIATE STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTERMEDIATE STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)